Yu-Chih Liu

Yu-Chih Liu

Auto-generated profile, based on publicly available information

Yu-Chih Liu

Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2017 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
YYYan Ye
Yan Ye
BZBidong Zhang
Bidong Zhang
RMRuifeng Mao
Ruifeng Mao
CZChenhua Zhang
Chenhua Zhang
YWYulan Wang
Yulan Wang
MZMingyue Zheng
Mingyue Zheng
Protein arginine methyltransferase 5 (PRMT5) is a type II PRMT enzyme critical for diverse cellular processes and different types of cancers. Many efforts have been made to discover novel scaffold PRMT5 inhibitors. Herein, we report the discovery of DC_P33 as a hit compound of PRMT5 inhibitor, identified by molecular docking based virtual screening and 3H-labeled radioactive methylation assays. Structure–activity relationship (SAR) analysis was performed on the analogs of DC_P33 and then structural modifications were done to improve its activity. Among the derivatives, the compound DC_C01 displayed an IC50 value of 2.8 μM, and good selectivity toward PRMT1, EZH2 and DNMT3A. Moreover, DC_C01 exhibited anti-proliferation activities against Z-138, Maver-1, and Jeko-1 cancer cells with EC50 values of 12 μM, 12 μM, and 10.5 μM, respectively. Taken together, these results contribute to the development of specific inhibitors against PRMT5 and cancer therapy.

1 September 2019 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
WKWei-Ke Kuo
Wei-Ke Kuo
YLYu-Chih Liu
Yu-Chih Liu
CMChu Chien Ming
Chu Chien Ming
CHChung-Ching Hua
Chung-Ching Hua
CHChih-Yu Huang
Chih-Yu Huang
CWChao-Hung Wang
Chao-Hung Wang
Background: The BODE index is a multidimensional grading system for predicting the prognoses of patients with chronic obstructive pulmonary disease (COPD). This study investigated whether an amino acids-based metabolic profile developed for heart failure patients (including histidine, ornithine, phenylalanine, and leucine) could identify COPD patients and further discriminates COPD patients in advanced BODE stages. Methods: Ultra-performance liquid chromatography was performed on 119 participants, including 75 COPD patients at different BODE stages and 44 normal controls. Albumin, pre-albumin, transferrin, high sensitivity C-reactive protein, and hand grip strength were also measured. Receiver operating characteristic curves and area under curves were used for estimation. Results: The BODE points in our patients were 3.29 [95% confidence interval (CI) = 2.74–3.85]. Compared to normal controls, COPD patients had lower leucine but higher ornithine levels. A COPD score, developed based on leucine and ornithine, significantly discriminated COPD from normal controls [odds ratio (OR) = 2.71, 95% CI = 1.83–4.04, p <0.001]. A COPD score of ≥ 3.00 had an OR of 15.58 (95% CI = 5.96–40.73, p <0.001). In COPD patients from BODE 1 to BODE 4, the levels of histidine, ornithine and phenylalanine increased significantly. In multivariable analysis, histidine and phenylalanine were independently able to distinguish BODE stages 3 and 4 from BODE 1 and were adopted to develop a metabolic score. Metabolic scores identified patients at BODE 3 and 4 (OR = 2.74, 95% CI =1.41–5.29, p = 0.003) better than hand grip strength, high sensitive C-reactive protein, albumin, pre-albumin, and transferrin value. A metabolic score of ≥9.53 significantly discriminated BODE 3 and 4 from BODE 1 and 2 (OR = 8.56, 95% CI = 2.77–26.39, p <0.001). Conclusion: Amino acid-based COPD score and metabolic score discriminate COPD patients from normal controls, and identify patients in advanced stages of COPD.

1 May 2008 in Proceedings of the Institution of Mechanical Engineers, Part B: Journal of Engineering Manufacture
Verified
Journal Article
Closed access
PCPei-Chann Chang
Pei-Chann Chang
Chin Yuan FanChin Yuan Fan
Chin Yuan Fan
JLJ Y-C Liu
J Y-C Liu
WHW-H Huang
W-H Huang
There are specific characteristics in the thin film transistor liquid crystal display (TFT-LCD) industry, such as unexpected demand fluctuation, customized products that each customer will designate a specific key component, long lead time of procurement, and short product life cycle. This research presents a genetic algorithm integrated with a neural network model for monthly sales forecasting of TFT-LCD products in Taiwan. The practical situation and its requirements are explained and two systematic approaches are discussed: (a) a K-means clustering for historic sales data and new sales is forecasted by mapping its inputs into one of these clustered data, and (b) a neural network integrated with a genetic algorithm for supervised learning of the functional behaviour of time-series data and their approximation. The evolving neural network model is applied for modelling the system's behaviour with the possibility of exploiting expert information and systematic optimization. The model has been tested and satisfying results are shown with practical data.